Sector
PharmaceuticalsOpen
₹1,332.4Prev. Close
₹1,326.1Turnover(Lac.)
₹24,437.14Day's High
₹1,335Day's Low
₹1,318.252 Week's High
₹1,421.4952 Week's Low
₹1,020Book Value
₹355.77Face Value
₹1Mkt Cap (₹ Cr.)
1,10,598.04P/E
20.68EPS
64.1Divi. Yield
0.621 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
27 Jul 2024
12:00 AM
Split
7 May 2024
12:00 AM
AGM
Announcement Date: 07 May, 2024
As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share costs and responsibilities.
Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.
The board has recommended a final dividend of ₹8 per equity share for FY 2024–25
Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | -15.7 | -43.6 | -76.9 | -113.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,256.5 | 20,517.8 | 18,413.1 | 17,097.2 |
Net Worth | 24,240.8 | 20,474.2 | 18,336.2 | 16,983.7 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 14,405.2 | 13,349.1 | 11,850.4 | 9,359.3 |
yoy growth (%) | 7.91 | 12.64 | 26.61 | -3.7 |
Raw materials | -5,045.9 | -4,123 | -3,573.8 | -2,631 |
As % of sales | 35.02 | 30.88 | 30.15 | 28.11 |
Employee costs | -2,434.6 | -2,270.1 | -2,030.2 | -1,843 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 2,223.8 | 3,056.2 | 2,775.8 | 696.99 |
Depreciation | -814.3 | -835 | -789.2 | -774.1 |
Tax paid | -600.6 | -869.8 | 161.9 | -130.1 |
Working capital | 1,395.8 | 1,078.3 | 508.8 | -170.1 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.91 | 12.64 | 26.61 | -3.7 |
Op profit growth | -17.3 | 9.31 | 115.77 | -23.81 |
EBIT growth | -27.1 | 9.89 | 271.62 | -52.56 |
Net profit growth | -25.75 | -25.57 | 418.2 | -59.04 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 32,553.5 | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 32,553.5 | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 |
Other Operating Income | 90.4 | 94.7 | 81.8 | 106.1 | 75.3 |
Other Income | 1,119 | 909 | 1,092.5 | 554.7 | 339.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Co-Chairman & Managing Directo
G V Prasad
Executive Chairman
K Satish Reddy
Independent Director
Shikha Sanjaya Sharma
Lead Independent Director
Leo Puri
Independent Director
K P Krishnan
Independent Director
Pennv Wan
Company Sec. & Compli. Officer
K Randhir Singh
Independent Director
Arun M. Kumar
Independent Director
Claudio Albrecht
Independent Director
Sanjiv Mehta
Independent Director
Alpna Seth
8-2-337 Road No 3,
Banjara Hills,
Telangana - 500034
Tel: 91-40-49002900
Website: http://www.drreddys.com
Email: shares@drreddys.com; mail@drreddys.com
3rd Flr 306 Rightwin,
Amrutha Ville, Somajiguda,
Hyderabad-500082
Tel: 91-40-23374967/23370
Website: www.bigshareonline.com
Email: bsshyd@bigshareonline.com
Summary
Dr Reddys Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Phar...
Read More
Reports by Dr Reddys Laboratories Ltd
What is the Dr Reddys Laboratories Ltd share price today?
What is the Market Cap of Dr Reddys Laboratories Ltd?
What is the PE and PB ratio of Dr Reddys Laboratories Ltd?
What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?
What is the CAGR of Dr Reddys Laboratories Ltd?
What is the shareholding pattern of Dr Reddys Laboratories Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
